The full house immunofluorescence pattern is the classic histopathologic finding of lupus and lupus nephritis. Glomerular deposits staining for IgG, IgA, IgM, C3 and C1q can help confirm a suspected diagnosis of SLE. But what about patients with negative immunofluorescence and no proliferative or membranous features?
Dr. John Cush RheumNow
1 year 4 months ago
Full read overview of Discoid Lupus. https://t.co/G6lXWTRSFn https://t.co/yjVsDg0D5d
Dr. John Cush RheumNow
1 year 4 months ago
Betw 2005 -2021, there was a substantial increase in HCQ use, but only modest steroid (GC) reductions. Swedish cohort study of 3891 SLE pts - over 5 yrs GC decr from 68% - 54% to 46%. HCQ increased by 29% over 5 years. https://t.co/6LZVMt9zy7 https://t.co/WunjnBBTW9
Dr. John Cush RheumNow
1 year 4 months ago
Telitacicept, recombinant fusion protein targeting BLyS & APRIL, studied in 41 Chinese SLE pts (added to standard Rx) showed mean improvements in SLEDAI-2K (10.0 to 6.25 @12 wks & 4.2 @24 wks;p<.001), daily prednisone (21 mg to 9.8mg) & proteinuria (2.8 gr to 1.3 gr/day) https://t.co/xtPMSZBoWg
Dr. John Cush RheumNow
1 year 4 months ago
Vitamin D Headlines (5.9.2025)
Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy.
https://t.co/i9OJrYR59T https://t.co/PQ3fAR5teR
Dr. John Cush RheumNow
1 year 4 months ago
Telemedicine and Lupus
https://t.co/RgfgnMGsZw https://t.co/uQEYLlrlB5
Dr. John Cush RheumNow
1 year 4 months ago
TONIGHT! Tuesday Night Rheumatology: π Lupus Unlocked: Cutaneous SLE
Join us for a discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE.
Featuring:
Dr. Victoria P. Werth
Dr. Matilda Nicholas
Dr. Anthony Fernandez
Dr. Christopher https://t.co/l0QjM9obk2
Investigators from the Netherlands have published their findings that smoking is a risk factor in rheumatoid arthritis (RA), led by the induction of local autoimmune responses at mucosal sites (in the lungs) and exemplified by RA-specific autoantibodies.
Dr. John Cush RheumNow
1 year 4 months ago
Is the nosology of CPPD outdated? Pseudogout to chondrocalcinosis? In 2011 EULAR taskforce rec the preferred term "calcium pyrophosphate deposition dz". G-CAN aims to update & standardised terminology for CPPD, requiring change to ICD-10 & adoption by societies https://t.co/wTdc0Tosc6
Dr. John Cush RheumNow
1 year 4 months ago
Managing CKD in Lupus Nephritis
Dr. Hans-Joachim Anders explores how to treat LN patients with chronic kidney disease, balancing disease control and renal preservation.
π― Donβt miss these expert pearls.
π Full update on RheumNow: https://t.co/frHvcd1xMw
#LupusNephritis https://t.co/VedtGaHkMj
Dr. John Cush RheumNow
1 year 4 months ago
Soluble CD13 (sCD13) has pro-inflammatory effects & is elevated in severe COVID-19. sCD13 is chemotactic, angiogenic, & arthritogenic. In COVID-19, sCD13 was assoc w/ sCD13 severity, ethnicity, inflammation markers, NETosis, & vascular injury/thrombosis. https://t.co/dTT9X49DIt
Recent reports on small numbers of lupus patients treated with CAR-T cells directed against CD19+ B lymphocytes have generated considerable excitement, not so much because the initial response to this therapy was favorable, but because after follow-up durations of two years or longer the patients were reported to have an ongoing clinical remission without the need for further treatment and in the absence of most autoantibodies. This state has

